Aptevo Therapeutics (APVO) Total Current Liabilities (2016 - 2025)
Aptevo Therapeutics (APVO) has disclosed Total Current Liabilities for 11 consecutive years, with $5.6 million as the latest value for Q3 2025.
- Quarterly Total Current Liabilities fell 4.56% to $5.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Sep 2025, down 4.56% year-over-year, with the annual reading at $6.2 million for FY2024, 14.08% down from the prior year.
- Total Current Liabilities hit $5.6 million in Q3 2025 for Aptevo Therapeutics, up from $4.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $34.8 million in Q4 2021 to a low of $4.9 million in Q2 2025.
- Historically, Total Current Liabilities has averaged $12.7 million across 5 years, with a median of $6.9 million in 2023.
- Biggest five-year swings in Total Current Liabilities: surged 340.79% in 2021 and later tumbled 77.31% in 2022.
- Year by year, Total Current Liabilities stood at $34.8 million in 2021, then tumbled by 74.95% to $8.7 million in 2022, then dropped by 17.02% to $7.2 million in 2023, then fell by 14.08% to $6.2 million in 2024, then decreased by 9.55% to $5.6 million in 2025.
- Business Quant data shows Total Current Liabilities for APVO at $5.6 million in Q3 2025, $4.9 million in Q2 2025, and $5.4 million in Q1 2025.